93392 Federal Register / Vol. 89, No. 228 / Tuesday, November 26, 2024 / Notices 

1These criteria may be found in APPENDIX A TO 

PART 391—MEDICAL ADVISORY CRITERIA, 

section H. Epilepsy: § 391.41(b)(8), paragraphs 3, 4, 

scoping period will also be considered 

during the development of the Draft EIS. 

TVA expects to release the Draft EIS 

in late 2025. TVA anticipates holding a 

community meeting near JOF after 

releasing the Draft EIS. Meeting details 

will be posted on TVA’s website and 

advertised in local media. TVA expects 

to release the Final EIS in Summer 

2026. 

Michael McCall, 

Vice President, Environment and 

Sustainability. 

[FR Doc. 2024–27844 Filed 11–22–24; 4:15 pm] 

BILLING CODE 8120–01–P 

DEPARTMENT OF TRANSPORTATION 

Federal Motor Carrier Safety 

Administration 

[Docket No. FMCSA–2024–0028] 

Qualification of Drivers; Exemption 

Applications; Epilepsy and Seizure 

Disorders 

AGENCY: Federal Motor Carrier Safety 

Administration (FMCSA), Department 

of Transportation (DOT). 

ACTION: Notice of applications for 

exemption; request for comments. 

SUMMARY: FMCSA announces receipt of 

applications from 13 individuals for an 

exemption from the prohibition in the 

Federal Motor Carrier Safety 

Regulations (FMCSRs) against persons 

with a clinical diagnosis of epilepsy or 

any other condition that is likely to 

cause a loss of consciousness or any loss 

of ability to control a commercial motor 

vehicle (CMV) to drive in interstate 

commerce. If granted, the exemptions 

would enable these individuals who 

have had one or more seizures and are 

taking anti-seizure medication to 

operate CMVs in interstate commerce. 

DATES: Comments must be received on 

or before December 26, 2024. 

ADDRESSES: You may submit comments 

identified by the Federal Docket 

Management System Docket No. 

FMCSA–2024–0028 using any of the 

following methods: 

• Federal eRulemaking Portal: Go to 

www.regulations.gov/, insert the docket 

number (FMCSA–2024–0028) in the 

keyword box and click ‘‘Search.’’ Next, 

choose the only notice listed, and click 

on the ‘‘Comment’’ button. Follow the 

online instructions for submitting 

comments. 

• Mail: Dockets Operations; U.S. 

Department of Transportation, 1200 

New Jersey Avenue SE, West Building 

Ground Floor, Washington, DC 20590– 

0001. 

• Hand Delivery: West Building 

Ground Floor, 1200 New Jersey Avenue 

SE, Washington, DC, 20590–0001 

between 9 a.m. and 5 p.m. ET Monday 

through Friday, except Federal 

Holidays. 

• Fax: (202) 493–2251. 

To avoid duplication, please use only 

one of these four methods. See the 

‘‘Public Participation’’ portion of the 

SUPPLEMENTARY INFORMATION section for 

instructions on submitting comments. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Christine A. Hydock, Chief, Medical 

Programs Division, FMCSA, DOT, 1200 

New Jersey Avenue SE, Washington, DC 

20590–0001, (202) 366–4001, 

fmcsamedical@dot.gov. Office hours are 

8:30 a.m. to 5 p.m. ET Monday through 

Friday, except Federal holidays. If you 

have questions regarding viewing or 

submitting material to the docket, 

contact Dockets Operations, (202) 366– 

9826. 

SUPPLEMENTARY INFORMATION: 

I. Public Participation 

A. Submitting Comments 

If you submit a comment, please 

include the docket number for this 

notice (Docket No. FMCSA–2024–0028), 

indicate the specific section of this 

document to which each comment 

applies, and provide a reason for each 

suggestion or recommendation. You 

may submit your comments and 

material online or by fax, mail, or hand 

delivery, but please use only one of 

these means. FMCSA recommends that 

you include your name and a mailing 

address, an email address, or a phone 

number in the body of your document 

so that FMCSA can contact you if there 

are questions regarding your 

submission. 

To submit your comment online, go to 

https://www.regulations.gov/docket/ 

FMCSA–2024–0028. Next, choose the 

only notice listed, click the ‘‘Comment’’ 

button, and type your comment into the 

text box on the following screen. Choose 

whether you are submitting your 

comment as an individual or on behalf 

of a third party and then submit. 

If you submit your comments by mail 

or hand delivery, submit them in an 

unbound format, no larger than 81⁄2 by 

11 inches, suitable for copying and 

electronic filing. FMCSA will consider 

all comments and material received 

during the comment period. 

B. Viewing Comments 

To view comments go to 

www.regulations.gov. Insert the docket 

number (FMCSA–2024–0028) in the 

keyword box and click ‘‘Search.’’ Next, 

choose the only notice listed, and click 

‘‘Browse Comments.’’ If you do not have 

access to the internet, you may view the 

docket online by visiting Dockets 

Operations on the ground floor of the 

DOT West Building, 1200 New Jersey 

Avenue SE, Washington, DC 20590– 

0001, between 9 a.m. and 5 p.m. ET 

Monday through Friday, except Federal 

holidays. To be sure someone is there to 

help you, please call (202) 366–9317 or 

(202) 366–9826 before visiting Dockets 

Operations. 

C. Privacy Act 

In accordance with 49 U.S.C. 

31315(b)(6), DOT solicits comments 

from the public on the exemption 

request. DOT posts these comments, 

without edit, including any personal 

information the commenter provides, to 

www.regulations.gov. As described in 

the system of records notice DOT/ALL 

14 (Federal Docket Management 

System), which can be reviewed at 

https://www.transportation.gov/ 

individuals/privacy/privacy-act-systemrecords-notices, the comments are 

searchable by the name of the submitter. 

II. Background 

Under 49 U.S.C. 31136(e) and 

31315(b), FMCSA may grant an 

exemption from the FMCSRs for no 

longer than a 5-year period if it finds 

such exemption would likely achieve a 

level of safety that is equivalent to, or 

greater than, the level that would be 

achieved absent such exemption. The 

statutes also allow the Agency to renew 

exemptions at the end of the 5-year 

period. FMCSA grants medical 

exemptions from the FMCSRs for a 2- 

year period to align with the maximum 

duration of a driver’s medical 

certification. 

The 13 individuals listed in this 

notice have requested an exemption 

from the epilepsy and seizure disorders 

prohibition in 49 CFR 391.41(b)(8). 

Accordingly, the Agency will evaluate 

the qualifications of each applicant to 

determine whether granting the 

exemption will achieve the required 

level of safety mandated by statute. 

The physical qualification standard 

for drivers regarding epilepsy found in 

§ 391.41(b)(8) states that a person is 

physically qualified to drive a CMV if 

that person has no established medical 

history or clinical diagnosis of epilepsy 

or any other condition which is likely 

to cause the loss of consciousness or any 

loss of ability to control a CMV. 

In addition to the regulations, FMCSA 

has published advisory criteria 1 to 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 228 / Tuesday, November 26, 2024 / Notices 93393 

and 5, which is available on the internet at https:// 

www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/ 

CFR-2015-title49-vol5-part391-appA.pdf. 

assist medical examiners (MEs) in 

determining whether drivers with 

certain medical conditions are qualified 

to operate a CMV in interstate 

commerce. 

The criteria states that if an individual 

has had a sudden episode of a nonepileptic seizure or loss of 

consciousness of unknown cause that 

did not require anti-seizure medication, 

the decision whether that person’s 

condition is likely to cause the loss of 

consciousness or loss of ability to 

control a CMV should be made on an 

individual basis by the ME in 

consultation with the treating physician. 

Before certification is considered, it is 

suggested that a 6-month waiting period 

elapse from the time of the episode. 

Following the waiting period, it is 

suggested that the individual have a 

complete neurological examination. If 

the results of the examination are 

negative and anti-seizure medication is 

not required, then the driver may be 

qualified. 

In those individual cases where a 

driver has had a seizure or an episode 

of loss of consciousness that resulted 

from a known medical condition (e.g., 

drug reaction, high temperature, acute 

infectious disease, dehydration, or acute 

metabolic disturbance), certification 

should be deferred until the driver has 

recovered fully from that condition, has 

no existing residual complications, and 

is not taking anti-seizure medication. 

Drivers who have a history of 

epilepsy/seizures, off anti-seizure 

medication, and seizure-free for 10 

years, may be qualified to operate a 

CMV in interstate commerce. Interstate 

drivers with a history of a single 

unprovoked seizure may be qualified to 

drive a CMV in interstate commerce if 

seizure-free and off anti-seizure 

medication for a 5-year period or more. 

As a result of MEs misinterpreting 

advisory criteria as regulation, 

numerous drivers have been prohibited 

from operating a CMV in interstate 

commerce based on the fact that they 

have had one or more seizures and are 

taking anti-seizure medication, rather 

than an individual analysis of their 

circumstances by a qualified ME based 

on the physical qualification standards 

and medical best practices. 

On January 15, 2013, FMCSA 

announced in a notice of final 

disposition titled, ‘‘Qualification of 

Drivers; Exemption Applications; 

Epilepsy and Seizure Disorders,’’ (78 FR 

3069), its decision to grant requests from 

22 individuals for exemptions from the 

regulatory requirement that interstate 

CMV drivers have ‘‘no established 

medical history or clinical diagnosis of 

epilepsy or any other condition which 

is likely to cause loss of consciousness 

or any loss of ability to control a CMV.’’ 

Since that time, the Agency has 

published additional notices granting 

requests from individuals for 

exemptions from the regulatory 

requirement regarding epilepsy found in 

§ 391.41(b)(8). 

To be considered for an exemption 

from the epilepsy and seizure disorders 

prohibition in § 391.41(b)(8), applicants 

must meet the criteria in the 2007 

recommendations of the Agency’s 

Medical Expert Panel (78 FR 3069). 

III. Qualifications of Applicants 

Timothy Andersen 

Timothy Andersen is a 39-year-old 

class D license holder in Wisconsin. 

They have a history of epilepsy and 

have been seizure free since 2006. They 

take anti-seizure medication with the 

dosage and frequency remaining the 

same since November 20, 2013. Their 

physician states that they are supportive 

of Timothy Andersen receiving an 

exemption. 

Randson Burdette 

Randson Burdette is a 33-year-old 

class D license holder in Ohio. They 

have a history of epilepsy and have been 

seizure free since 2005. They have not 

taken anti-seizure medication since 

2016. Their physician states that they 

are supportive of Randson Burdette 

receiving an exemption. 

Giovanni Dale 

Giovanni Dale is a 33-year-old class R 

license holder in Mississippi. They have 

a history of epilepsy and have been 

seizure free since 2007. They take antiseizure medication with the dosage and 

frequency remaining the same since 

2008. Their physician states that they 

are supportive of Giovanni Dale 

receiving an exemption. 

Robert Edwards 

Robert Edwards is a 37-year-old class 

C license holder in Nevada. They have 

a history of tonic-clonic seizures and 

have been seizure free since June 2014. 

They take anti-seizure medication with 

the dosage and frequency remaining the 

same since June 2014. Their physician 

states that they are supportive of Robert 

Edwards receiving an exemption. 

Chad Johnson 

Chad Johnson is a 53-year-old class C 

license holder in Iowa. They have a 

history of seizure disorder and have 

been seizure free since 2003. They take 

anti-seizure medication with the dosage 

and frequency remaining the same since 

2004. Their physician states that they 

are supportive of Chad Johnson 

receiving an exemption. 

Austin Little 

Austin Little is a 29-year-old class C 

license holder in Pennsylvania. They 

have a history of epilepsy and have been 

seizure free since December 24, 2015. 

They take anti-seizure medication with 

the dosage and frequency remaining the 

same since 2015. Their physician states 

that they are supportive of Austin Little 

receiving an exemption. 

Denton O’Conner 

Denton O’Conner is a 36-year-old 

class D license holder in New York. 

They have a history of tonic-clonic 

seizures and have been seizure free 

since August 2012. They have not taken 

anti-seizure medication since September 

2016. Their physician states that they 

are supportive of Denton O’Conner 

receiving an exemption. 

Monroe Peterson 

Monroe Peterson is a 34-year-old class 

C license holder in Iowa. They have a 

history of seizure disorder and have 

been seizure free since 2014. They take 

anti-seizure medication with the dosage 

and frequency remaining the same since 

August 2014. Their physician states that 

they are supportive of Monroe Peterson 

receiving an exemption. 

Austin Rodriguez 

Austin Rodriguez is a 29-year-old 

class C license holder in California. 

They have a history of primary 

generalized epilepsy and have been 

seizure free since April 12, 2007. They 

take anti-seizure medication with the 

dosage and frequency remaining the 

same since 2013. Their physician states 

that they are supportive of Austin 

Rodriguez receiving an exemption. 

Wayne Scaggs 

Wayne Scaggs is a 35-year-old class D 

license holder in Ohio. They have a 

history of epilepsy and have been 

seizure free since 2016. They take antiseizure medication with the dosage and 

frequency remaining the same since July 

2016. Their physician states that they 

are supportive of Wayne Scaggs 

receiving an exemption. 

Richard Sievers 

Richard Sievers is a 53-year-old class 

ABCD commercial driver’s license 

(CDL) holder in Wisconsin. They have 

a history of complex partial seizures and 

have been seizure free since 2014. They 

take anti-seizure medication with the 


lotter on DSK11XQN23PROD with NOTICES1
93394 Federal Register / Vol. 89, No. 228 / Tuesday, November 26, 2024 / Notices 

dosage and frequency remaining the 

same since 2019. Their physician states 

that they are supportive of Richard 

Sievers receiving an exemption. 

Beth Smith 

Beth Smith is a 58-year-old class D 

license holder in Montana. They have a 

history of epilepsy and have been 

seizure free since April 26, 2013. They 

take anti-seizure medication with the 

dosage and frequency remaining the 

same since November 2013. Their 

physician states that they are supportive 

of Beth Smith receiving an exemption. 

Brandon White 

Brandon White is a 35-year-old class 

AM1 CDL holder in California. They 

have a history of generalized tonicclonic seizures related to epilepsy and 

have been seizure free since March 11, 

2011. They take anti-seizure medication 

with the dosage and frequency 

remaining the same since February 

2013. Their physician states that they 

are supportive of Brandon White 

receiving an exemption. 

IV. Request for Comments 

In accordance with 49 U.S.C. 31136(e) 

and 31315(b), FMCSA requests public 

comment from all interested persons on 

the exemption petitions described in 

this notice. We will consider all 

comments received before the close of 

business on the closing date indicated 

under the DATES section of the notice. 

Larry W. Minor, 

Associate Administrator for Policy. 

[FR Doc. 2024–27668 Filed 11–25–24; 8:45 am] 

BILLING CODE 4910–EX–P 

DEPARTMENT OF TRANSPORTATION 

Federal Motor Carrier Safety 

Administration 

[Docket No. FMCSA–2014–0102; FMCSA– 

2014–0104; FMCSA–2014–0384; FMCSA– 

2017–0057; FMCSA–2017–0058; FMCSA– 

2018–0136; FMCSA–2022–0035; FMCSA– 

2022–0037] 

Qualification of Drivers; Exemption 

Applications; Hearing 

AGENCY: Federal Motor Carrier Safety 

Administration (FMCSA), Department 

of Transportation (DOT). 

ACTION: Notice of renewal of 

exemptions; request for comments. 

SUMMARY: FMCSA announces its 

decision to renew exemptions for 13 

individuals from the hearing 

requirement in the Federal Motor 

Carrier Safety Regulations (FMCSRs) for 

interstate commercial motor vehicle 

(CMV) drivers. The exemptions enable 

these hard of hearing and deaf 

individuals to continue to operate CMVs 

in interstate commerce. 

DATES: Each group of renewed 

exemptions were applicable on the 

dates stated in the discussions below 

and will expire on the dates provided 

below. Comments must be received on 

or before December 26, 2024. 

ADDRESSES: You may submit comments 

identified by the Federal Docket 

Management System Docket No. 

FMCSA–2014–0102, Docket No. 

FMCSA–2014–0104, Docket No. 

FMCSA–2014–0384, Docket No. 

FMCSA–2017–0057, Docket No. 

FMCSA–2017–0058, Docket No. 

FMCSA–2018–0136, Docket No. 

FMCSA–2022–0035, or Docket No. 

FMCSA–2022–0037 using any of the 

following methods: 

• Federal eRulemaking Portal: Go to 

www.regulations.gov/, insert the docket 

number (FMCSA–2014–0102, FMCSA– 

2014–0104, FMCSA–2014–0384, 

FMCSA–2017–0057, FMCSA–2017– 

0058, FMCSA–2018–0136, FMCSA– 

2022–0035, or FMCSA–2022–0037) in 

the keyword box and click ‘‘Search.’’ 

Next, sort the results by ‘‘Posted 

(Newer-Older),’’ choose the first notice 

listed, and click on the ‘‘Comment’’ 

button. Follow the online instructions 

for submitting comments. 

• Mail: Dockets Operations; U.S. 

Department of Transportation, 1200 

New Jersey Avenue SE, West Building 

Ground Floor, Washington, DC 20590– 

0001. 

• Hand Delivery: West Building 

Ground Floor, 1200 New Jersey Avenue 

SE, Washington, DC 20590–0001, 

between 9 a.m. and 5 p.m. ET Monday 

through Friday, except Federal holidays. 

• Fax: (202) 493–2251. 

To avoid duplication, please use only 

one of these four methods. See the 

‘‘Public Participation’’ portion of the 

SUPPLEMENTARY INFORMATION section for 

instructions on submitting comments. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Christine A. Hydock, Chief, Medical 

Programs Division, FMCSA, DOT, 1200 

New Jersey Avenue SE, Room W64–224, 

Washington, DC 20590–0001, (202) 366– 

4001, fmcsamedical@dot.gov. Office 

hours are 8:30 a.m. to 5 p.m. ET Monday 

through Friday, except Federal holidays. 

If you have questions regarding viewing 

or submitting material to the docket, 

contact Dockets Operations, (202) 366– 

9826. 

SUPPLEMENTARY INFORMATION: 

I. Public Participation 

A. Submitting Comments 

If you submit a comment, please 

include the docket number for this 

notice (Docket No. FMCSA–2014–0102, 

Docket No. FMCSA–2014–0104, Docket 

No. FMCSA–2014–0384, Docket No. 

FMCSA–2017–0057, Docket No. 

FMCSA–2017–0058, Docket No. 

FMCSA–2018–0136, Docket No. 

FMCSA–2022–0035, or Docket No. 

FMCSA–2022–0037), indicate the 

specific section of this document to 

which each comment applies, and 

provide a reason for each suggestion or 

recommendation. You may submit your 

comments and material online or by fax, 

mail, or hand delivery, but please use 

only one of these means. FMCSA 

recommends that you include your 

name and a mailing address, an email 

address, or a phone number in the body 

of your document so that FMCSA can 

contact you if there are questions 

regarding your submission. 

To submit your comment online, go to 

www.regulations.gov/, insert the docket 

number (FMCSA–2014–0102, FMCSA– 

2014–0104, FMCSA–2014–0384, 

FMCSA–2017–0057, FMCSA–2017– 

0058, FMCSA–2018–0136, FMCSA– 

2022–0035, or FMCSA–2022–0037) in 

the keyword box and click ‘‘Search.’’ 

Next, sort the results by ‘‘Posted 

(Newer-Older),’’ choose the first notice 

listed, click the ‘‘Comment’’ button, and 

type your comment into the text box on 

the following screen. Choose whether 

you are submitting your comment as an 

individual or on behalf of a third party 

and then submit. 

If you submit your comments by mail 

or hand delivery, submit them in an 

unbound format, no larger than 81⁄2 by 

11 inches, suitable for copying and 

electronic filing. FMCSA will consider 

all comments and material received 

during the comment period. 

B. Viewing Comments 

To view comments go to 

www.regulations.gov. Insert the docket 

number (FMCSA–2014–0102, FMCSA– 

2014–0104, FMCSA–2014–0384, 

FMCSA–2017–0057, FMCSA–2017– 

0058, FMCSA–2018–0136, FMCSA– 

2022–0035, or FMCSA–2022–0037) in 

the keyword box and click ‘‘Search.’’ 

Next, sort the results by ‘‘Posted 

(Newer-Older),’’ choose the first notice 

listed, and click ‘‘Browse Comments.’’ If 

you do not have access to the internet, 

you may view the docket online by 

visiting Dockets Operations on the 

ground floor of the DOT West Building, 

1200 New Jersey Avenue SE, 

Washington, DC 20590–0001, between 9 

a.m. and 5 p.m. ET Monday through 


lotter on DSK11XQN23PROD with NOTICES1